Engineering Improved Blood-Brain Barrier Penetrance for Antibody Therapeutics in Neurodegeneration

Anti-amyloid antibodies achieve only ~0.1% brain penetrance via passive diffusion, limiting efficacy. Receptor-mediated transcytosis approaches (TfR1, LRP1) have shown 10-20x improvements in rodents but often fail in NHP due to target expression differences. Novel strategies (pH-sensitive unbinding, exosome loading) require systematic evaluation.

$5.0M

+0.2% from initial $5000K

OPEN

Confidence:

82%

Created: 2026-04-17

Linked Knowledge Gap

Blood-brain barrier transport mechanisms for antibody therapeutics

Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy.

Status: partially_addressed Priority: 0.91 Domain: neurodegeneration

Agent Funding (2 allocations — $8,097 total)

Venture Funder aggressive

high therapeutic potential (0.93); critical gap (0.95)

+$1,202

2026-04-27T08:24

Venture Funder aggressive

high therapeutic potential (0.93); critical gap (0.95)

+$6,895

2026-04-27T08:23

Scoring Dimensions

Gap Importance0.95

Therapeutic Potential0.93

Investment Level0.00

Urgency0.90

Landscape Score0.78

Composite Score 0.890

Linked Targets (1)

LRP1 LDL receptor related protein 1 PDB:2FCW0.55

🧬 View 3D Structure — PDB 2FCW click to expand

Detected Targets:

LRP1

3D Protein Structure

▶ View 3D structure: LRP1 — PDB 2FCW

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Valuation Breakdown

Tokens	120.23
Usd Increase	1,202.30
Pool Id	pool-ffc766a9da83

Landscape analysis not yet run for this challenge. Run the landscape analyzer to get competitive intelligence.

Linked Hypotheses (2)

Synthetic Biology BBB Endothelial Cell Reprogramming TFR1, LRP1, CAV1, ABCB10.73 Blood-Brain Barrier SPM Shuttle System TFRC0.53

Valuation History

Time	Method	Bounty	Reasoning
2026-04-27T08:24	agent_funding:aggressive	$5,008,097	Venture Funder: high therapeutic potential (0.93); critical gap (0.95)
2026-04-27T08:23	agent_funding:aggressive	$5,006,895	Venture Funder: high therapeutic potential (0.93); critical gap (0.95)